The China National Medical Products Administration has accepted Zai Lab’s (NASDAQ:ZLAB) supplemental
New Drug Application (sNDA) for ZEJULA (niraparib) as a maintenance
treatment of adult patients with advanced epithelial ovarian, fallopian
tube, or primary peritoneal cancer who are in a complete or partial
response to first-line platinum-based chemotherapy.
Zai Lab in-licensed rights to ZEJULA from GSK for Mainland China, Hong Kong and Macau.
Shares are down 1% premarket.
https://seekingalpha.com/news/3551976-zai-labs-snda-for-zeluja-okd-in-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.